SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

BACKGROUND: Lurbinectedin recently received FDA accelerated approval as a second line treatment option for metastatic small cell lung cancer (SCLC). However, there are currently no established biomarkers to predict SCLC sensitivity or resistance to lurbinectedin or preclinical studies to guide ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kundu, Kiran, Cardnell, Robert J., Zhang, Bingnan, Shen, Li, Stewart, C. Allison, Ramkumar, Kavya, Cargill, Kasey R., Wang, Jing, Gay, Carl M., Byers, Lauren A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674596/
https://www.ncbi.nlm.nih.gov/pubmed/35004241
http://dx.doi.org/10.21037/tlcr-21-437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674596/
https://www.ncbi.nlm.nih.gov/pubmed/35004241
http://dx.doi.org/10.21037/tlcr-21-437

Ejemplares similares